In September 2010, pegloticase (Krystexxa; Savient Pharmaceuticals), a recombinant urate oxidase conjugated to polyethylene glycol (PEG), was approved by the US Food and Drug Administration (FDA) for the treatment of chronic gout in adult patients refractory to conventional therapy.
This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Richette, P. & Bardin, T. Gout. Lancet 375, 318–328 (2010).
Palmer, D. G., Highton, J. & Hessian, P. A. Development of the gout tophus. An hypothesis. Am. J. Clin. Pathol. 91, 190–195 (1989).
Burns, C. M. & Wortmann, R. L. Gout therapeutics: new drugs for an old disease. Lancet 16 Aug 2010 (doi:10.1016/S0140-6736(10)60665-4).
Zhang, W. et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann. Rheum. Dis. 65, 1312–1324 (2006).
Pascual, E. et al. Febuxostat. Nature Rev. Drug Discov. 8, 191–192 (2008).
Sundy, J. S. et al. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum. 56, 1021–1028 (2007).
Sundy, J. S. et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum. 58, 2882–2891 (2008).
US Food and Drug Administration. FDA labelling information — Krystexxa (pegloticase). FDA website [online], (2010).
Thiele, R. G. & Schlesinger, N. Ultrasonography shows active inflammation in clinically unaffected joints in chronic tophaceous gout. Arthritis Rheum. 60, S565 (2009).
Mandel, D. R. et al. Use of pegloticase in chronic gout refractory to conventional therapy is associated with significant clinical benefit: tender joint and swollen joint counts and patient global assessment (Health Assessment Questionnaire). Arthritis Rheum. 62, S166 (2010).
Schlesinger, N. et al. Efficacy of canakinumab (ACZ885), a fully human anti-interleukin (IL)-1beta monoclonal antibody, in the prevention of flares in gout patients initiating allopurinol therapy. Arthritis Rheum. 62, S2087 (2010)
Terkeltaub, R. et al. Evaluation of rilonacept for prevention of gout flares during initiation of urate-lowering therapy: results of a phase 3, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 62, S152 (2010).
Baert, F. et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348, 601–608 (2003).
IMS MIDAS (2010).
Richter, S. & Ekas, L. Collins Stewart Report on Savient Pharmaceuticals. (Collins Stewart, 5 Nov 2010),
Werher, C. Summer Street Report on Savient Pharmaceuticals. (Summer Street, 8 Nov 2010).
U.Y. would like to thank D. Hanicq for assistance in data collection.
Naomi Schlesinger has acted as a consultant for and received grants from Novartis, has been part of the speakers bureau for Takeda, and has participated in advisory boards for novartis, Takeda, URL Pharma, Savient and RX Enzyme.
About this article
Cite this article
Schlesinger, N., Yasothan, U. & Kirkpatrick, P. Pegloticase. Nat Rev Drug Discov 10, 17–18 (2011). https://doi.org/10.1038/nrd3349
Current Rheumatology Reports (2021)
Acta Pharmacologica Sinica (2019)
Pharmaceutical Research (2017)
A Numerical Approach for Kinetic Analysis of the Nonexponential Thermoinactivation Process of Uricase
The Protein Journal (2016)
Phosphorylcholine polymer nanocapsules prolong the circulation time and reduce the immunogenicity of therapeutic proteins
Nano Research (2016)